This mini-exon is created through a process called alternative splicing, in which cells include or exclude specific snippets of genetic material to slightly alter the structure -- and function ...

The Boston-based biotech delivers DNA constructs, using a range of vehicles, which are transcribed into exon RNA, driving the production of full length, healthy proteins. Like gene therapy ...

Ascidian Therapeutics will receive $42 million upfront from Roche, and up to $1.8 billion in milestone payments and royalties, to discover RNA exon editing candidates for neurological diseases.

The approval was based on data from the phase 3 PAPILLON trial (ClinicalTrials.gov Identifier: NCT04538664), which included 308 patients with advanced or metastatic NSCLC with EGFR exon 20 ...

Exon-skipping therapy group: $115,934 and $1,010,571, an 8-fold increase Branded glucocorticoid group: $22,309 and $91,319, a 4-fold increase Generic glucocorticoid group: $30,035 and $35,020, a 1 ...

NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not ...

A Texas man named Jeffrey Exon was accused of murdering his 2-year-old toddler daughter Aurora Exon by starving her, back in 2021. On Monday, Exon was convicted in her death of several charges ...

Jeffrey J. Exon, 47, was found guilty by a Shawnee County District Court jury on Monday over the death of Aurora Exon, The Topeka Capital-Journal reports. Police were called by Exon to his Topeka ...

Rybrevant outperformed other therapies for patients with exon 20 insertion-mutant, advanced non-small cell lung cancer in a clinical trial, highlighting the importance of personalized medicine.

Jeffrey J. "James" Exon's 2-year-old daughter, Aurora Exon, died of malnutrition due to neglect by her father at a time when he was "intoxicated and passed out in his bed for days on end ...

Although the EGFR exon 20 insertion–positive mutation accounts for a small minority of patients with non­–small cell lung cancer (NSCLC), there is a promising pipeline, said Marcia Horn, JD ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...